Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ADVM Adverum Biotechnologies	$2.54 -6.6%	$2.46	$1.78 ▼ $10.14	$53.06M	0.7	263,911 shs	65,761 shs
CHRS Coherus Oncology	$0.88 +1.5%	$0.81	$0.66 ▼ $2.43	$102.02M	0.86	2.67 million shs	1.68 million shs
CRTX Cortexyme	$1.82 +2.2%	$1.24	$1.78 ▼ $40.66	$54.88M	1.4	620,672 shs	494,899 shs
MESO Mesoblast	$11.11 +0.8%	$11.20	$5.78 ▼ $22.00	$1.42B	2.39	278,163 shs	242,362 shs
TSHA Taysha Gene Therapies	$2.64 +3.5%	$2.54	$1.05 ▼ $3.31	$566.71M	0.97	2.94 million shs	3.29 million shs

Elon Musk's Next Move

Explore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ADVM Adverum Biotechnologies	0.00%	+6.50%	-1.93%	-25.95%	-67.35%
CHRS Coherus Oncology	0.00%	+9.86%	+11.34%	+5.28%	-38.46%
CRTX Cortexyme	+2.25%	+13.04%	+45.60%	+82.00%	+152.78%
MESO Mesoblast	0.00%	+2.97%	-8.63%	+9.57%	+49.53%
TSHA Taysha Gene Therapies	0.00%	+10.00%	-0.38%	+112.05%	+16.81%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ADVM Adverum Biotechnologies	4.5845 of 5 stars	3.4	4.0	0.0	4.8	2.7	2.5	0.6
CHRS Coherus Oncology	3.7968 of 5 stars	3.3	0.0	0.0	4.5	2.2	2.5	0.6
CRTX Cortexyme	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
MESO Mesoblast	2.3375 of 5 stars	3.5	3.0	0.0	0.0	2.0	0.8	0.6
TSHA Taysha Gene Therapies	4.0593 of 5 stars	4.5	5.0	0.0	0.0	2.6	3.3	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ADVM Adverum Biotechnologies	2.80	Moderate Buy	$23.80	837.01% Upside
CHRS Coherus Oncology	2.67	Moderate Buy	$4.68	432.20% Upside
CRTX Cortexyme	0.00	N/A	N/A	N/A
MESO Mesoblast	3.00	Buy	$18.00	62.02% Upside
TSHA Taysha Gene Therapies	3.00	Buy	$8.17	209.34% Upside

Current Analyst Ratings Breakdown

Latest ADVM, MESO, TSHA, CRTX, and CHRS Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/11/2025	TSHA Taysha Gene Therapies	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$8.00
7/1/2025	TSHA Taysha Gene Therapies	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$8.00
6/26/2025	ADVM Adverum Biotechnologies	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$16.00 ➝ $12.00
6/10/2025	TSHA Taysha Gene Therapies	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$8.00
6/3/2025	TSHA Taysha Gene Therapies	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$9.00 ➝ $11.00
6/2/2025	TSHA Taysha Gene Therapies	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$6.00 ➝ $8.00
5/29/2025	TSHA Taysha Gene Therapies	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform
5/29/2025	TSHA Taysha Gene Therapies	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Market Outperform ➝ Market Outperform	$5.00 ➝ $6.00
5/29/2025	TSHA Taysha Gene Therapies	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$7.00 ➝ $9.00
5/16/2025	TSHA Taysha Gene Therapies	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$8.00 ➝ $9.00
5/15/2025	ADVM Adverum Biotechnologies	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Sector Perform ➝ Sector Perform	$5.00 ➝ $4.00

(Data available from 7/13/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ADVM Adverum Biotechnologies	$1M	53.06	N/A	N/A	$3.40 per share	0.75
CHRS Coherus Oncology	$266.96M	0.38	$0.29 per share	3.02	($1.14) per share	-0.77
CRTX Cortexyme	N/A	N/A	N/A	N/A	$3.97 per share	N/A
MESO Mesoblast	$5.90M	240.62	N/A	N/A	$4.21 per share	2.64
TSHA Taysha Gene Therapies	$8.33M	68.03	N/A	N/A	$0.35 per share	7.54

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ADVM Adverum Biotechnologies	-$130.93M	-$6.40	N/A	N/A	N/A	N/A	-130.53%	-66.31%	8/11/2025 (Estimated)
CHRS Coherus Oncology	$28.51M	-$1.13	N/A	N/A	N/A	-66.30%	N/A	-26.51%	8/6/2025 (Estimated)
CRTX Cortexyme	-$89.94M	-$2.97	N/A	N/A	N/A	N/A	-70.96%	-63.53%	N/A
MESO Mesoblast	-$87.96M	N/A	0.00	N/A	N/A	N/A	N/A	N/A	7/29/2025 (Estimated)
TSHA Taysha Gene Therapies	-$89.30M	-$0.34	N/A	N/A	N/A	-1,201.08%	-104.93%	-50.09%	8/11/2025 (Estimated)

Latest ADVM, MESO, TSHA, CRTX, and CHRS Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/15/2025	Q1 2025	TSHA Taysha Gene Therapies	-$0.08	-$0.08	N/A	-$0.08	$1.48 million	$2.30 million
5/12/2025	Q1 2025	CHRS Coherus Oncology	-$0.31	-$0.35	-$0.04	-$0.49	$59.79 million	$7.60 million
4/15/2025	Q4 2024	ADVM Adverum Biotechnologies	-$1.34	-$1.96	-$0.62	-$1.96	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ADVM Adverum Biotechnologies	N/A	N/A	N/A	N/A	N/A
CHRS Coherus Oncology	N/A	N/A	N/A	N/A	N/A
CRTX Cortexyme	N/A	N/A	N/A	N/A	N/A
MESO Mesoblast	N/A	N/A	N/A	N/A	N/A
TSHA Taysha Gene Therapies	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ADVM Adverum Biotechnologies	N/A	3.57	3.57
CHRS Coherus Oncology	N/A	1.22	1.20
CRTX Cortexyme	N/A	9.92	9.92
MESO Mesoblast	0.22	0.96	0.63
TSHA Taysha Gene Therapies	0.77	5.35	5.35

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ADVM Adverum Biotechnologies	48.17%
CHRS Coherus Oncology	72.82%
CRTX Cortexyme	63.18%
MESO Mesoblast	1.43%
TSHA Taysha Gene Therapies	77.70%

Insider Ownership

Company	Insider Ownership
ADVM Adverum Biotechnologies	6.00%
CHRS Coherus Oncology	8.08%
CRTX Cortexyme	27.90%
MESO Mesoblast	18.80%
TSHA Taysha Gene Therapies	3.78%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ADVM Adverum Biotechnologies	190	20.89 million	19.64 million	Optionable
CHRS Coherus Oncology	330	115.93 million	106.57 million	Optionable
CRTX Cortexyme	55	30.15 million	21.74 million	Not Optionable
MESO Mesoblast	80	127.78 million	103.76 million	Optionable
TSHA Taysha Gene Therapies	180	214.66 million	206.55 million	Optionable

ADVM, MESO, TSHA, CRTX, and CHRS Headlines

Recent News About These Companies

B of A Securities Initiates Coverage of Taysha Gene Therapies (TSHA) with Buy Recommendation

July 12 at 10:13 AM | msn.com

Taysha Gene Therapies (NASDAQ:TSHA) Trading Up 5.7% - What's Next?

July 11 at 1:52 PM | marketbeat.com

Bank of America Initiates Coverage on Taysha Gene Therapies (NASDAQ:TSHA)

July 11 at 8:49 AM | marketbeat.com

Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

July 3, 2025 | globenewswire.com

Beyond The Numbers: 10 Analysts Discuss Taysha Gene Therapies Stock

July 1, 2025 | benzinga.com

Taysha Gene Therapies (NASDAQ:TSHA) Earns "Buy" Rating from Needham & Company LLC

July 1, 2025 | marketbeat.com

Cantor Fitzgerald Reiterates “Overweight” Rating on Taysha (TSHA) for Positive TSHA-102 Clinical Data

June 29, 2025 | insidermonkey.com

Taysha Gene Therapies (NASDAQ:TSHA) Stock Price Down 4.3% - Here's What Happened

June 26, 2025 | marketbeat.com

Taysha Gene Therapies (NASDAQ:TSHA) Trading Down 4.9% - Here's Why

June 20, 2025 | marketbeat.com

Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Receives Average Rating of "Buy" from Brokerages

June 19, 2025 | marketbeat.com

Equities Analysts Offer Predictions for TSHA FY2025 Earnings

June 16, 2025 | marketbeat.com

Taysha Gene Therapies Grants Stock Options to New Employees Under Inducement Plan

June 8, 2025 | nasdaq.com

Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

June 6, 2025 | globenewswire.com

Taysha Gene Therapies Releases TSHA-102 Clinical Program Updates

June 4, 2025 | insidermonkey.com

Retail Buzz Surges Around Taysha Gene Therapies After Positive Rett Syndrome Trial Data

June 4, 2025 | msn.com

Paul B. Manning Buys 750,000 Shares of Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Stock

June 4, 2025 | insidertrades.com

Taysha Gene Therapies Highlights TSHA-102 Program Advancements for Rett Syndrome at 2025 IRSF Scientific Meeting

June 3, 2025 | quiverquant.comQ

Taysha Gene Therapies Announces Details for Oral Presentations at the 2025 IRSF Rett Syndrome Scientific Meeting Reviewing Recent Updates from the TSHA-102 Clinical Program

June 3, 2025 | globenewswire.com

6TSHA : Where Taysha Gene Therapies Stands With Analysts

June 2, 2025 | benzinga.com

Taysha Gene Therapies Announces Pivotal Part B Trial Design Details for TSHA-102 in Rett Syndrome Enabled by IRSF Natural History Data and Positive Clinical Data from Part A of ...

May 30, 2025 | morningstar.comM

Taysha Gene Therapies (TSHA) Price Target Raised by JMP on Positive Rett Syndrome Trial Data

May 30, 2025 | msn.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

ADVM, MESO, TSHA, CRTX, and CHRS Company Descriptions

Adverum Biotechnologies NASDAQ:ADVM

$2.54 -0.18 (-6.62%)

Closing price 07/11/2025 04:00 PM Eastern

Extended Trading

$2.50 -0.04 (-1.77%)

As of 07/11/2025 05:02 PM Eastern

Adverum Biotechnologies, Inc., a clinical-stage company, develops gene therapy product candidates to treat ocular diseases. Its lead product candidate is ixoberogene soroparvovec (ADVM-022), a single intravitreal injection gene therapy candidate used for the treatment of patients with wet age-related macular degeneration and diabetic macular edema which is in phase 2 clinical trials. The company is developing ADVM-062 (AAV.7m8-L-opsin), a novel gene therapy product candidate for the treatment of blue cone monochromacy via a single IVT injection. Adverum Biotechnologies, Inc. has license and collaboration agreements with University of California; GenSight Biologics; Lexeo Therapeutics; and Virovek, Inc. The company was formerly known as Avalanche Biotechnologies, Inc. and changed its name to Adverum Biotechnologies, Inc. in May 2016. Adverum Biotechnologies, Inc. was incorporated in 2006 and is headquartered in Redwood City, California.

Coherus Oncology NASDAQ:CHRS

$0.88 +0.01 (+1.48%)

Closing price 07/11/2025 04:00 PM Eastern

Extended Trading

$0.88 +0.00 (+0.34%)

As of 07/11/2025 07:24 PM Eastern

Coherus BioSciences, Inc., a biopharmaceutical company, focuses on the research, development, and commercialization of cancer treatments primarily in the United States. The company develops UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte-colony stimulating factor; LOQTORZI, a novel PD-1 inhibitor; and Casdozokitug, an investigational recombinant human immunoglobulin isotype G1 (IgG1) monoclonal antibody targeting interleukin 27. It is also developing CHS-114, an investigational highly specific human afucosylated IgG1 monoclonal antibody selectively targeting CCR8, a chemokine receptor highly expressed on Treg cells in the tumor microenvironment (TME); and CHS-1000, an antibody targeting human ILT4 designed to improve anti-PD-1 clinical benefit by transforming an unfavorable TME to a more favorable TME. In addition, the company's licensed immuno-oncology programs include NZV930, an antibody designed to inhibit cluster of differentiation 73; and GSK4381562, an antibody targeting CD112R for the treatment of solid tumors. Further, it offers YUSIMRY, a biosimilar to Humira for the treatment of patients with inflammatory diseases characterized by increased production of tumor necrosis factor (TNF) in the body, including rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, psoriasis, and ulcerative colitis. It collaboration agreement with Junshi Biosciences for the co-development and commercialization of toripalimab; agreement with Surface and Adimab LLC; license agreements with Bioeq AG and Genentech, Inc., as well as Vaccinex, Inc.; and out-licensing agreement with Novartis Institutes for Biomedical Research, Inc. and GlaxoSmithKline Intellectual Property No. 4 Limited. The company was formerly known as BioGenerics, Inc. and changed its name to Coherus BioSciences, Inc. in April 2012. Coherus BioSciences, Inc. was incorporated in 2010 and is headquartered in Redwood City, California.

Cortexyme NASDAQ:CRTX

$1.82 +0.04 (+2.25%)

As of 07/11/2025

Cortexyme, Inc., a clinical stage biopharmaceutical company, focuses on developing therapeutics for Alzheimer's and other degenerative diseases. Its lead drug candidate is atuzaginstat (COR388), an orally administered brain-penetrating small molecule gingipain inhibitor, which is in Phase II/III clinical trial for use in patients with mild to moderate Alzheimer's disease, as well as for the treatment of oral squamous cell carcinoma, periodontitis, and coronavirus infection. The company was incorporated in 2012 and is headquartered in South San Francisco, California.

Mesoblast NASDAQ:MESO

$11.11 +0.09 (+0.82%)

Closing price 07/11/2025 04:00 PM Eastern

Extended Trading

$11.11 0.00 (0.00%)

As of 07/11/2025 07:57 PM Eastern

Mesoblast Limited engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells. The company offers Remestemcel-L that is in Phase III clinical trials for the treatment of systemic inflammatory diseases, including steroid refractory acute graft versus host disease, acute respiratory distress syndrome, and biologic refractory inflammatory bowel disease; and Remestemcel-L, which is in Phase III clinical trials to treat chronic heart failure and chronic low back pain due to degenerative disc disease. It is also developing MPC-300-IV to treat biologic refractory rheumatoid arthritis diabetic nephropathy; and MPC-25-IC for the treatment or prevention of acute myocardial infarction. It has strategic partnerships with Tasly Pharmaceutical Group to offer MPC-150-IM for heart failure and MPC-25-IC for heart attacks in China; JCR Pharmaceuticals Co. Ltd. to treat wound healing in patients with epidermolysis bullosa; and Grünenthal to develops and commercializes cell therapy for the treatment of chronic low back pain. The company was incorporated in 2004 and is headquartered in Melbourne, Australia.

Taysha Gene Therapies NASDAQ:TSHA

$2.64 +0.09 (+3.53%)

Closing price 07/11/2025 04:00 PM Eastern

Extended Trading

$2.64 +0.00 (+0.19%)

As of 07/11/2025 06:58 PM Eastern

Taysha Gene Therapies, Inc., a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis. Taysha Gene Therapies, Inc. has a strategic partnership with The University of Texas Southwestern Medical Center. Taysha Gene Therapies, Inc. was incorporated in 2019 and is headquartered in Dallas, Texas.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time